Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Jasper Rip
  • Rudi W. HendriksEmail author
  • Odilia B. J. Corneth
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101553


Historical Background

Bruton’s tyrosine kinase (BTK), a member of the Tec family of nonreceptor kinases, is expressed in all hematopoietic cells except T and NK cells and functions in many different signaling pathways (Table 1). It functions as a crucial signaling molecule downstream of many receptors, including the B cell receptor (BCR) on B lymphocytes. Loss-of-function mutations in the Btk gene were shown to drive X-linked agammaglobulinemia (XLA), an inherited immunodeficiency disease marked by near absence of peripheral B cells and circulating immunoglobulins (Ig), first described by Dr. O.C. Bruton in 1952. Since this discovery, many striking findings have contributed to our understanding of the role of Btk in B cell development and function (Fig. 1).
BTK, Table 1

Btk is involved in signaling pathways downstream of various receptors on different immune cell types


This is a preview of subscription content, log in to check access.


  1. Amsbaugh DF, Hansen CT, Prescott B, Stashak PW, Barthold DR, Baker PJ. Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J Exp Med. 1972;136:931–49.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Aoki Y, Isselbacher KJ, Pillai S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci USA. 1994;91:10606–9.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8.PubMedGoogle Scholar
  4. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.  https://doi.org/10.1056/NEJMoa1215637.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.  https://doi.org/10.1056/NEJMoa1509981.CrossRefPubMedCentralPubMedGoogle Scholar
  6. Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022–35.  https://doi.org/10.1158/2159-8290. CD-14-0098 [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  7. Corneth OB, Klein Wolterink RG, Hendriks RW. BTK signaling in B cell differentiation and autoimmunity. Curr Top Microbiol Immunol. 2016;393:67–105.  https://doi.org/10.1007/82_2015_478.CrossRefPubMedCentralPubMedGoogle Scholar
  8. de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93–104.PubMedPubMedCentralCrossRefGoogle Scholar
  9. de Weers M, Brouns GS, Hinshelwood S, Kinnon C, Schuurman RK, Hendriks RW, et al. B-cell antigen receptor stimulation activates the human Bruton’s tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem. 1994;269:23857–60.PubMedCentralPubMedGoogle Scholar
  10. Hendriks RW, de Bruijn MF, Maas A, Dingjan GM, Karis A, Grosveld F. Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J. 1996;15:4862–72.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–32.  https://doi.org/10.1038/nrc3702.CrossRefPubMedCentralPubMedGoogle Scholar
  12. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–80.  https://doi.org/10.1073/pnas.1004594107.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Pearl ER, Vogler LB, Okos AJ, Crist WM, Lawton 3rd AR, Cooper MD. B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states. J Immunol. 1978;120:1169–75.PubMedCentralPubMedGoogle Scholar
  14. Rawlings DJ, Witte ON. The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Semin Immunol. 1995;7:237–46.  https://doi.org/10.1006/smim.1995.0028.CrossRefPubMedCentralPubMedGoogle Scholar
  15. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 2012;12:282–94.  https://doi.org/10.1038/nri3190.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–90.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Tsukada S, Simon MI, Witte ON, Katz A. Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc Natl Acad Sci USA. 1994;91:11256–60.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–33.  https://doi.org/10.1038/361226a0.CrossRefPubMedCentralPubMedGoogle Scholar
  19. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.  https://doi.org/10.1056/NEJMoa1306220.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94.  https://doi.org/10.1056/NEJMoa1400029.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Jasper Rip
    • 1
  • Rudi W. Hendriks
    • 1
    Email author
  • Odilia B. J. Corneth
    • 1
  1. 1.Department of Pulmonary MedicineErasmus Medical Center RotterdamRotterdamThe Netherlands